Hosted on MSN1mon
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?myChoiceCDx Progresses Well: Myriad Genetics' FDA-approved tumor test determines HRD status in patients with ovarian cancer. Earlier, the company had announced plans to expand the test to other ...
KUALA LUMPUR, June 12 (Bernama) -- Myriad Genetics Inc announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade ...
Myriad Genetics, Inc. MYGN recently announced ... Score (“GIS”) to determine Homologous Recombination Deficiency (“HRD”) will be reported for all samples analyzed with Illumina’s updated ...
underscore its commitment to improving access to HRD diagnostic testing. Yet, a volatile macroeconomic situation and competitive disadvantages may hurt Myriad Genetics’ operations. In the past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback